Phase II Trial of Bevacizumab in Combination with Temozolomide for Upfront Treatment of Elderly Patients with Newly-Diagnosed Glioblastoma Multiforme
A study for elderly individuals with malignant brain tumors using experimental drug, bevacizumab combined with temozolomide
Sponsor: Jonsson Comprehensive Cancer Center
Enrolling: Male and Female Patients
IRB Number: AAAK7100
U.S. Govt. ID: NCT01149850
Contact: Fabio Iwamoto: 212-342-0571 / fi2146@columbia.edu
Additional Study Information: The purpose of this study is to find out whether an experimental drug, bevacizumab with temozolomide is safe when given to elderly patients with brain tumors and investigate the side effects of the drug combination and how often they occur. This study will also explore whether bevacizumab and temozolomide can be effective in shrinking tumors when given to elderly patients with brain tumors without giving radiation therapy.
This study is closed
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Have you had prior radiotherapy to the brain? Yes No
Are you willing to forego drug therapy against the tumor while being treated with bevacizumab and temozolomide? Yes No
Have you received chemotherapy wafer implants (Gliadel wafers)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Fabio Iwamoto
fi2146@columbia.edu
212-342-0571
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE